Grufity logoGrufity logo

Aclaris Therapeutics Inc Stock Research

ACRS

17.48USD+0.66(+3.92%)Market Closed

Market Summary

USD17.48+0.66
Market Closed
3.92%

ACRS Alerts

ACRS Stock Price

ACRS RSI Chart

ACRS Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-14.2

Price/Sales (Trailing)

49.6

EV/EBITDA

-11.61

Price/Free Cashflow

-17.6

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

81.72%

EBT Margin

-1479.64%

Return on Equity

-37.34%

Return on Assets

-30.67%

Free Cashflow Yield

-5.68%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

23.5M

Revenue Y/Y

1.0K%

Revenue Q/Q

1.1K%

ACRS Earnings

Earnings (TTM)

-82.1M

Earnings Y/Y

5.65%

Earnings Q/Q

2.82%

Price Action

52 Week Range

9.8418.96
(Low)(High)

Last 7 days

5.0%

Last 30 days

12.9%

Last 90 days

13.7%

Trailing 12 Months

73.1%

ACRS Financial Health

Current Ratio

12.97

Debt/Equity

0.05

Debt/Cashflow

-6.37

ACRS Investor Care

Shares Dilution (1Y)

8.92%

Diluted EPS (TTM)

-1.29

Peers (Alternatives to Aclaris Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
442.1B
96.0B
-4.77% 1.21%
23.08
4.6
5.02% 7.14%
308.1B
29.2B
-6.33% 46.49%
51.07
10.54
5.34% 1.02%
267.0B
59.0B
-5.13% 34.98%
17.49
4.53
27.84% 112.03%
245.5B
99.9B
-13.80% -15.92%
8.25
2.46
45.01% 53.21%
154.0B
46.7B
0.64% 15.96%
23.07
3.3
2.79% 223.53%
MID-CAP
5.0B
4.4B
10.03% -0.57%
-46.66
1.14
1.80% 57.67%
2.2B
659.0M
13.79% 40.18%
57.51
3.29
16.78% -53.92%
SMALL-CAP
1.9B
613.6M
24.42% -38.51%
-3.79
3.14
37.73% -7.19%
1.6B
3.1M
23.90% 79.89%
-5.08
503.44
-77.09% -12.24%
1.4B
-
33.79% -57.23%
-0.46
1.95
-4.11% -144.36%
1.2B
23.5M
12.85% 73.07%
-14.2
49.6
243.57% -1.04%
942.1M
112.7M
- -24.55%
-4.21
8.36
45.53% 40.26%
885.5M
-
-2.61% -19.99%
2.65
2.34
10.49% -16.07%
298.8M
49.7M
46.97% -25.95%
-5.03
6.01
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Aclaris Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue282.7%23,500,0006,141,0006,437,0006,761,0006,840,000
  S&GA Expenses-0.7%24,930,00025,096,00024,891,00023,619,00021,574,000
  R&D Expenses15.8%70,843,00061,163,00050,281,00043,813,00038,667,000
EBITDA0.0%-90,063,000.00-90,022,000.00---
EBITDA Margin-4.9%-14.67-13.99---
Earnings Before Taxes--90,865,000.00----
EBT Margin-4.8%-14.80-14.12---
Net Income1.4%-82,077,000.00-83,271,000.00-80,900,000.00-90,865,000.00-81,234,000.00
Net Income Margin74.2%-3.49-13.56-12.57-13.44-
Free Cahsflow3.9%-66,227,000.00-68,922,000.00-61,431,000.00-52,442,000.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-3.7%268278227251263
  Current Assets-1.1%257259191205206
    Cash Equivalents-9.7%6268362754
  Net PPE-10.3%11111
Liabilities13.2%4842465447
  Current Liabilities22.0%2016172318
Shareholder's Equity-6.8%220236180197217
  Retained Earnings-3.1%-654.68-634.73-614.20-595.41-572.60
  Additional Paid-In Capital0.5%876872795793789
Shares Outstanding0.0%6767626161
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations4.1%-65.53-68.32-60.87-52.13-43.92
  Share Based Compensation3.6%1414141413
Cashflow From Investing102.0%1-38.14-62.39-167.63-160.76
Cashflow From Financing18.9%7361124225233

Risks for ACRS

What is the probability of a big loss on ACRS?

100%


Probability that Aclaris Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Aclaris Therapeutics stock will be more than 30% underwater in next one year.

91.2%


Probability that Aclaris Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACRS

Cumulative Returns on ACRS

-3.4%


7-Year Cumulative Returns

-6.5%


5-Year Cumulative Returns

130.4%


3-Year Cumulative Returns

What are the long-term rolling returns for ACRS?

FIve years rolling returns for Aclaris Therapeutics.

Annualized Returns

Which funds bought or sold ACRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
STRS OHIO
added
82.91
260,000
573,000
-%
2023-01-25
Lindbrook Capital, LLC
reduced
-12.97
-724
3,276
-%
2023-01-23
Allspring Global Investments Holdings, LLC
reduced
-1.25
-11,415
1,028,580
-%
2023-01-18
Verition Fund Management LLC
added
122.61
7,054,000
11,726,000
0.07%
2023-01-12
Assenagon Asset Management S.A.
unchanged
-
2,000
3,070,000
0.01%
2023-01-06
MASSMUTUAL TRUST CO FSB/ADV
unchanged
-
-
1,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
850,000
850,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
5.84
168,000
1,033,000
-%
2022-11-17
Telemetry Investments, L.L.C.
sold off
-100
-154,000
-
-%
2022-11-16
BNP PARIBAS ARBITRAGE, SNC
added
57.77
145,241
331,705
-%

1–10 of 46

Latest Funds Activity

Are funds buying ACRS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ACRS
No. of Funds

Aclaris Therapeutics News

InvestorsObserver

Is Aclaris Therapeutics Inc (ACRS) a Leader in the Diagnostics & Research Industry?.

InvestorsObserver,
3 days ago

Investor's Business Daily

Armenian Reporter

Marketing Sentinel

St Louis Business Journal

Longtime leader of St. Louis startup investor to retire.

St Louis Business Journal ,
39 days ago

Philadelphia Business Journal

Schedule 13G FIlings of Aclaris Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 25, 2022
ra capital management, l.p.
7.1%
4,398,453
SC 13G
Feb 15, 2022
rock springs capital management lp
6.31%
3,861,347
SC 13G/A
Feb 14, 2022
venrock healthcare capital partners ii, l.p.
7.5%
4,563,962
SC 13G
Feb 11, 2022
foresite capital fund iii, l.p.
0.0%
0
SC 13G/A
Feb 04, 2022
blackrock inc.
6.7%
4,078,875
SC 13G
Feb 04, 2022
wellington management group llp
9.05%
5,539,268
SC 13G
Jan 24, 2022
biotechnology value fund l p
3.4%
2,093,085
SC 13G
Feb 16, 2021
rock springs capital management lp
6.24%
2,676,100
SC 13G/A
Feb 12, 2021
ecor1 capital, llc
3.5%
1,509,812
SC 13G/A
Feb 11, 2021
adage capital partners gp, l.l.c.
5.24%
2,250,000
SC 13G/A

ACRS Fair Value

Recent SEC filings of Aclaris Therapeutics

View All Filings
Date Filed Form Type Document
Jan 20, 2023
4
Insider Trading
Jan 09, 2023
8-K
Current Report
Jan 06, 2023
3
Insider Trading
Jan 06, 2023
8-K
Current Report
Jan 04, 2023
4
Insider Trading
Dec 16, 2022
4
Insider Trading
Dec 13, 2022
8-K
Current Report
Nov 22, 2022
8-K
Current Report
Nov 14, 2022
4
Insider Trading
Nov 08, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for ACRS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-04
Walker Neal
sold
-223,342
14.8895
-15,000
-
2023-01-03
Walker Neal
sold
-381,213
15.2485
-25,000
-
2022-12-15
Monahan Joseph
sold
-79,411.5
15.8823
-5,000
chief scientific officer
2022-11-14
SCHIFF ANDREW N
sold
-23,416.7
17.08
-1,371
-
2022-11-11
SCHIFF ANDREW N
sold
-702,177
17.0597
-41,160
-
2022-11-10
SCHIFF ANDREW N
sold
-193,995
17.0246
-11,395
-
2022-11-08
Powell Andrew Kenneth William
gifted
-
-
-4,000
-
2022-10-26
SCHIFF ANDREW N
sold
-247,253
17.005
-14,540
-
2022-10-25
SCHIFF ANDREW N
sold
-204,516
17.0175
-12,018
-
2022-10-24
SCHIFF ANDREW N
sold
-248,586
17.0078
-14,616
-

1–10 of 50

Neal S. Walker
80
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenue$ 19,018$ 1,659$ 21,999$ 5,260
Costs and expenses:    
Cost of revenue9231,0993,1463,564
Research and development expense23,65613,97656,74129,711
General and administrative expense5,8135,97917,98716,676
Licensing7,300 7,300 
Revaluation of contingent consideration2,200900(2,400)22,139
Total costs and expenses39,89221,95482,77472,090
Loss from operations(20,874)(20,295)(60,775)(66,830)
Other income (expense), net922(851)1,502(1,231)
Net loss$ (19,952)$ (21,146)$ (59,273)$ (68,061)
Net loss per share, basic$ (0.30)$ (0.35)$ (0.92)$ (1.23)
Net loss per share, diluted$ (0.30)$ (0.35)$ (0.92)$ (1.23)
Weighted average common shares outstanding, basic66,675,33761,219,32164,718,00855,215,037
Weighted average common shares outstanding, diluted66,675,33761,219,32164,718,00855,215,037
Other comprehensive (loss) income:    
Unrealized gain (loss) on marketable securities, net of tax of $0$ (139)$ 5$ (1,241)$ (5)
Foreign currency translation adjustment 176 96
Total other comprehensive (loss) income(139)181(1,241)91
Comprehensive loss(20,091)(20,965)(60,514)(67,970)
Contract research    
Revenues:    
Total revenue1,0901,4153,5294,556
Licensing    
Revenues:    
Total revenue17,89821418,378612
Other    
Revenues:    
Total revenue$ 30$ 30$ 92$ 92

ACRS Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 61,653$ 27,349
Short-term marketable securities186,409164,065
Accounts receivable, net597623
Prepaid expenses and other current assets7,91412,995
Total current assets256,573205,032
Marketable securities 34,242
Property and equipment, net1,1451,335
Intangible assets6,9927,048
Other assets2,9223,554
Total assets267,632251,211
Current liabilities:  
Accounts payable7,6679,985
Accrued expenses9,15410,051
Current portion of lease liabilities766693
Discontinued operations2,2022,202
Total current liabilities19,78922,931
Other liabilities1,6382,172
Contingent consideration26,00028,400
Deferred tax liability367367
Total liabilities47,79453,870
Commitments and contingencies (Note 16)
Stockholders' Equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.00001 par value; 100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 66,679,641 and 61,228,446 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively11
Additional paid-in capital875,982792,971
Accumulated other comprehensive loss(1,465)(224)
Accumulated deficit(654,680)(595,407)
Total stockholders' equity219,838197,341
Total liabilities and stockholders' equity$ 267,632$ 251,211